Biological Safety Testing Market: Viral Safety Testing, Lab Automation & Growth Forecast

According to IMARC Group's latest research publication, The global biological safety testing market size was valued at USD 5.46 Billion in 2025 and is projected to reach USD 14.62 Billion by 2034, at a CAGR of 9.97% during 2026-2034.

How AI is Reshaping the Future of the Biological Safety Testing Market

• Automated Contaminant Detection: AI-powered image recognition and spectral analysis tools rapidly identify microbial contaminants, endotoxins, and foreign particles during testing, cutting manual review time significantly while improving detection accuracy across biopharmaceutical and vaccine pipelines.
• Predictive Risk Modelling for Regulatory Compliance: Machine learning models analyze historical testing data to flag likely compliance gaps before submissions, helping pharma companies address regulatory issues proactively and reduce costly product hold-ups.
• High-Throughput Screening Optimization: AI algorithms process data from thousands of simultaneous assay runs, identifying patterns and outliers that human analysts would miss, allowing labs to scale up testing volumes without proportional increases in staffing.

Explore Updated 2026 Market Trends & Analysis

Biological Safety Testing Industry Overview

The biological safety testing industry sits at the intersection of pharmaceutical innovation and regulatory accountability, making it one of the most non-negotiable parts of drug development. Global pharmaceutical R&D spending exceeded USD 300 billion in 2023, and every dollar invested in new biologics, vaccines, or cell and gene therapies ultimately requires rigorous safety validation before reaching patients.

Biological Safety Testing Market Trends and Drivers

The sheer volume of new biologics in development is one of the biggest reasons this market keeps growing. In 2023 alone, the FDA approved 25 biologics out of 55 newly approved drugs, including 12 monoclonal antibodies and a range of enzymes and proteins.

Regulatory agencies are not just maintaining standards; they are raising them. The EMA's Committee for Advanced Therapies issued a positive opinion for Durveqtix in May 2024, and decisions like this signal that advanced therapy approvals are becoming more frequent, each requiring highly specialized biological safety evaluations.

The competitive landscape in biological safety testing is shifting fast, driven by a wave of acquisitions and facility expansions. In September 2024, Eurofins acquired Modern Testing Services, strengthening its biological safety testing footprint across more than 35 locations in 20 countries.

Leading Companies Operating in the Global Biological Safety Testing Industry

• Avance Biosciences
• Charles River Laboratories
• Creative Biogene
• Eurofins Scientific
• Lonza Group AG
• Maravai LifeSciences
• Pace Analytical Services Inc.
• Pacific BioLabs
• Sartorius AG
• SGS SA
• ViruSure GmbH (Asahi Kasei Corporation)
• WuXi Biologics

Biological Safety Testing Market Report Segmentation

By Product and Services:

• Kits and Reagents
• Instruments
• Services

Kits and reagents lead the market with around 41.3% of market share in 2024.

By Test Type:

• Endotoxin Tests
• Sterility Tests
• Cell Line Authentication and Characterization Tests
• Bioburden Tests
• Residual Host Contaminant Detection Tests
• Adventitious Agent Detection Tests
• Others

Endotoxin tests lead the market with around 24.9% of market share in 2024.

By Application:

• Vaccine Development
• Blood Products Testing
• Cellular and Gene Therapy
• Tissue and Tissue-related Products Testing
• Stem Cell Research

Vaccine development leads the market with around 28.7% of market share in 2024. With over 13 billion COVID-19 vaccine doses administered globally by 2021 and ongoing development of mRNA-based.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the global market with over 38.8% market share in 2024, driven by the FDA's rigorous approval standards, a mature CRO ecosystem.

Recent News and Developments in the Biological Safety Testing Market

• November 2024: Maravai LifeSciences announced plans to acquire DNA and RNA assets from Officinae Bio, integrating AI-based nucleic acid technologies into its TriLink BioTechnologies division to advance mRNA manufacturing and biologics safety testing capabilities.
• October 2024: MilliporeSigma, the Life Science division of Merck KGaA, unveiled a EUR 290 million biosafety testing facility in Rockville, Maryland, described as the largest investment in contract testing in the company's history, built to support both conventional and advanced therapy modalities.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.